The standard of care for suspected or confirmed methemoglobinemia includes the administration of methylene blue, which acts as a reducing agent to convert methemoglobin back to hemoglobin, in conjunction with supportive measures such as oxygen supplementation and intravenous hydration. Here, HBG2 is linked to methemoglobinemia.